Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid

Drug Metabolism and Disposition

Volumn 34, Issue 9, 2006, Pages 1539-1545

  Bernard, Olivier ^a   Tojcic, Jelena ^a   Journault, Kim ^a   Perusse, Louis ^b   Guillemette, Chantal ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 2B7; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID ACYL GLUCURONIDE; MYCOPHENOLIC ACID PHENOLIC GLUCURONIDE; PHENOL DERIVATIVE; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CATALYSIS; CAUCASIAN; CONTROLLED STUDY; EXON; GENE SEQUENCE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; KIDNEY CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACYLATION; AFRICAN AMERICANS; BIOTRANSFORMATION; CELL LINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; ISOENZYMES; KINETICS; MICROSOMES; MUTATION, MISSENSE; MYCOPHENOLIC ACID; PHENOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; TRANSFECTION;

EID: 33747830531     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.010553     Document Type: Article

References (44)

1. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, and Belanger A (2000) 3′-Azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28:497-502.
2. Basu NK, Kole L, Kubota S, and Owens IS (2004) Human UDP- glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 32:768-773.
3. Bernard O and Guillemette C (2004) The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775-778.
4. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, and Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10:679-685.
5. Bowalgaha K and Miners JO (2001) The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
6. Bullingham R, Monroe S, Nicholls A, and Hale M (1996) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 36:315-324.
7. Bullingham RE, Nicholls AJ, and Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429-455.
8. Butler LM, Duguay Y, Millikan RC, Sinha R, Gagne JF, Sandler RS, and Guillemette C (2005) Joint effects between UDP-glucuronosyltransferase 1A7 genotype and dietary carcinogen exposure on risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14:1626-1632.
9. Cheng Z, Radominska-Pandya A, and Tephly TR (1998) Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. Arch Biochem Biophys 356:301-305.
10. Coffman BL, King CD, Rios GR, and Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73-77.
11. Cohn RG, Mirkovich A, Dunlap B, Burton P, Chiu SH, Eugui E, and Caulfield JP (1999) Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 68:411-418.
12. Duguay Y, Baar C, Skorpen F, and Guillemette C (2004) A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 75:223-233.
13. Ensom MH, Partovi N, Decarie D, Dumont RJ, Fradet G, and Levy RD (2002) Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Ther Drug Monit 24:310-314.
14. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, and Guillemette C (2004) Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14:501-515.
15. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, and Housman DE (2000) Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629-644.
16. Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude FJ, and Verpooten GA (1998) The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64:672-683.
17. Huang YH, Galijatovic A, Nguyen N, Geske D, Beaton D, Green J, Green M, Peters WH, and Tukey RH (2002) Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 12:287-297.
18. Innocenti F, Iyer L, Ramirez J, Green MD, and Ratain MJ (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686-692.
19. Jacobson PA, Green KG, and Hering BJ (2005) Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. J Clin Pharmacol 45:901-909.
20. Jin C, Miners JO, Lillywhite KJ, and Mackenzie PI (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 264:475-479.
21. Kuypers DR, Naesens M, Vermeire S, and Vanrenterghem Y (2005) The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78:351-361.
22. Lampe JW, Bigler J, Bush AC, and Potter JD (2000) Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol Biomarkers Prev 9:329-333.
23. Maes B, Oellerich M, Ceuppens JL, Armstrong VW, Evenepoel P, Kuypers D, Messiaen T, Shipkova M, Wieland E, and Vanrenterghem Y (2002) A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrol Dial Transplant 17:923-926.
24. Oellerich M, Shipkova M, Schutz E, Wieland E, Weber L, Tonshoff B, and Armstrong VW (2000) Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 22:20-26.
25. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, and Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33:139-146.
26. Radominska-Pandya A, Little JM, Pandya JT, Tephly TR, King CD, Barone GW, and Raufman JP (1998) UDP-glucuronosyltransferases in human intestinal mucosa. Biochim Biophys Acta 1394:199-208.
27. Schutz E, Shipkova M, Armstrong VW, Wieland E, and Oellerich M (1999) Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 45:419-422.
28. Seifeldin R (1995) Drug interactions in transplantation. Clin Ther 17:1043-1061.
29. Shipkova M, Strassburg CP, Braun F, Streit F, Grone HJ, Armstrong VW, Tukey RH, Oellerich M, and Wieland E (2001a) Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132:1027-1034.
30. Shipkova M, Wieland E, Schutz E, Wiese C, Niedmann PD, Oellerich M, and Armstrong VW (2001b) The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 33:1080-1081.
31. Simonen RL, Perusse L, Rankinen T, Rice T, Rao DC, and Bouchard C (2002) Familial aggregation of physical activity levels in the Quebec Family Study. Med Sci Sports Exerc 34:1137-1142.
32. Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225-232.
33. Srinivas TR, Meier-Kriesche HU, and Kaplan B (2005) Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 5:207-217.
34. Stephens M, Smith NJ, and Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
35. Thibaudeau J, Lepine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Tetu B, Jacob S, Perusse L, et al. (2006) Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res 66:125-133.
36. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
37. Turgeon D, Carrier JS, Levesque E, Hum DW, and Belanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787.
38. van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, et al. (1999) A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68:261-266.
39. van Gelder T, Klupp J, Barten MJ, Christians U, and Morris RE (2001) Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23:119-128.
40. Venkatakrishnan K, Von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.
41. Villeneuve L, Girard H, Fortier LC, Gagne JF, and Guillemette C (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307:117-128.
42. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, Zimmerhackl LB, Oellerich M, and Tonshoff B (2002) The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13:759-768.
43. Wieland E, Shipkova M, Schellhaas U, Schutz E, Niedmann PD, Armstrong VW, and Oellerich M (2000) Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 33:107-113.
44. Zheng Z, Fang JL, and Lazarus P (2002) Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 30:397-403.